ScreenerHero

BBOTBridgeBio Oncology Therapeutics Inc. Common Stock

NAS · US · Healthcare · Biotechnology · bbotx.com
9.080USD-5.42%Mkt Cap: 727.98M $P/E: —

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase maligna…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap727.98M $
Enterprise Value504.79M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-134.04M $
Revenue/Share—
Last Price9.080 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees88
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.76
PEG—
EV/EBITDA-2.54
EV/Revenue—
P/S—
P/B2.25
EPS (TTM)-2.15
EPS (Forward)-2.41
52W Range
7.01026% of range14.87
52W High14.87 USD
52W Low7.010 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-32.61%
ROA-29.90%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-113.89M $
CapEx (TTM)606.00K $
FCF Margin—
FCF Yield-12.36%
Net Debt-223.20M $
Net Debt/EBITDA1.12
Balance Sheet
Debt/Equity0.01
Current Ratio4.69
Quick Ratio4.38
Book Value/Sh4.033 USD
Cash/Share2.815 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)24.90 USD
Upside (mean)+174.2%
Target Range18.00 USD – 39.00 USD
$18.00+174.2% to mean$39.00
# Analysts10
Ownership
Shares Out.80.17M
Float35.81M
Insiders27.09%
Institutions70.97%
Short Interest
Short Ratio16.0d
Short % Float20.46%
Short % Out.7.27%
Shares Short5.83M
Short (prev mo.)5.21M
Technical
SMA 508.413 (+7.9%)
SMA 2009.975 (-9.0%)
Beta0.36
S&P 52W Chg18.16%
Avg Vol (30d)294.58K
Avg Vol (10d)262.57K
Technical Indicators
RSI (14)53.4
MACD0.2386
MACD Signal0.2243
MACD Hist.+0.0142
BB Upper9.714 USD
BB Middle8.890 USD
BB Lower8.067 USD
BB Width18.53%
ATR (14)0.5263 USD
Vol Ratio (20d)0.66x